Navigation Links
Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
Date:12/7/2016

SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has completed enrollment in the ralinepag phase 2 trial.  Ralinepag is an oral, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). The study enrolled approximately 60 patients at sites globally.

"This marks an important step in the development of ralinepag and is evidence of our strategic focus on our pipeline," said Amit Munshi, Arena's President and CEO. "We believe ralinepag has the potential to achieve a best-in-class profile for patients suffering from PAH and we look forward to seeing the results mid-year to confirm our hypothesis." 

The trial is a 22-week, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the effectiveness in reducing pulmonary vascular resistance, improving exercise capacity, tolerability and safety of ralinepag.   

About PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy. Based on data from the Registry to EValuate Early And Long-term PAH disease management (REVEAL) of patients in the United States, there is an estimated five-year survival rate of 57% from diagnosis.

About Ralinepag
Ralinepag, an orally available agonist of the IP receptor, is an investigational drug candidate internally discovered and developed by Arena and intended for the treatment of vascular diseases, including PAH. In Phase 1 trials, ralinepag showed an approximate 25-hour half-life, indicating that the compound could be dosed once or twice daily. Arena believes that ralinepag's high intrinsic potency and activity at the human IP receptor has the potential to improve treatment for patients with PAH. The FDA has granted ralinepag orphan drug status for the treatment of PAH.

About Arena Pharmaceuticals
We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.  We have three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis, APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH).  Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the ongoing Phase 2 program for ralinepag; the expected timing of clinical data; whether planned clinical trials for ralinepag can be completed; the improved treatment of patients with PAH; the advancement and potential of Arena's clinical programs; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.                                                 
Kevin R. Lind, Chief Financial Officer                  klind@arenapharm.com                                                                   
858.210.3636

Logo - http://photos.prnewswire.com/prnh/20161107/436843LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-completes-enrollment-in-ralinepag-phase-2-clinical-trial-for-pulmonary-arterial-hypertension-pah-300374081.html


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. How These Biotechs Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
2. Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
3. Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29
4. Deloitte Corporate Finance LLC Advises The Marena Group, Inc. on its Recapitalization with The Riverside Company
5. Arena Helps Power IoT Revolution
6. Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
7. Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
8. Arena Pharmaceuticals to Host Analyst & Investor Day on December 3rd
9. Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
10. Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10
11. Arena Pharmaceuticals Initiates a Phase 1b Clinical Trial of APD371
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... TORONTO (PRWEB) , ... November ... ... the most rapidly growing drug class and have a major impact in ... patients, important challenges still need to be overcome. Among these, defining valuable ...
(Date:11/11/2019)... ... ... 1st, Dr. Todd M. Britten and the team at Britten Periodontics & Implant Dentistry held ... aware that dental coverage for veterans for major dental surgery can be very hard to ... as many veterans as they could. Dr. Britten says he owes the success of the ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... with extraordinary surgical skills. As a trained sculptor and painter, he combines his ... natural-looking results for each patient. Dr. Sadati has made appearances on TV and ...
Breaking Medicine Technology:
(Date:11/9/2019)... ... ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to address the legal needs ... and advocacy assistance to families and patients in need. The announcement was made at ... of Blaine (“Fin”) Fogg, who was a member of the Boards of Trustees of ...
(Date:11/7/2019)... ... ... ALZYN, LLC today announced that The Silicon Review Magazine has named ALZYN, LLC ... 50 Best Companies to Watch 2019 program identifies companies which are successful in bringing ... on this list indicates the company has distinguished itself from peers by proving itself ...
(Date:11/7/2019)... , ... November 07, 2019 , ... ... co-founder of Ignite and Expand got together on the Shamangelic Healing Podcast ... of downloads skyrocketed. With a trending focus on learning ways to use bio-hacking ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... the participants’ connection to the God of their understanding, as well as, to ... and achieve their life’s purpose, fate, and fortune. , The next Trivedi ...
(Date:11/6/2019)... SOMERSET, N.J. and FRAKFURT, Germany (PRWEB) , ... ... ... Catalent, the leading global provider of advanced delivery technologies, development, and ... announced that its Chair and Chief Executive Officer, John Chiminski, has received ...
Breaking Medicine News(10 mins):